Sequelae and survivorship in patients treated with 131 I-MIBG therapy

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 565-572

  Sze, W C C ^a   Grossman, A B ^b   Goddard, I ^a   Amendra, D ^a   Shieh, S C C ^a   Plowman, P N ^a   Drake, W M ^a   Akker, S A ^a   Druce, M R ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; SOMATOSTATIN DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; ARTIFICIAL EMBOLISM; BONE METASTASIS; CANCER CHEMOTHERAPY; CHROMAFFIN CELL TUMOR; CHRONIC MYELOID LEUKEMIA; ENDOCRINE TUMOR; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MESENTERY; METASTASIS; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PARAGANGLIOMA; PERITONEUM METASTASIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; CHROMAFFIN CELLS; COHORT STUDIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84883150254     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.365     Document Type: Article

References (46)

1. Barakat MT, Meeran K, Bloom SR (2004) Neuroendocrine tumours. Endocr Relat Cancer 11: 1-18.
2. Basu B, Sirohi B, Corrie P (2010) Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 17: R75-R90.
3. Bomanji JB, Papathanasiou ND (2012) (1)(1)(1)In-DTPA(0)-octreotide (Octreoscan), (1)(3)(1)I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging 39(Suppl 1): S113-S125.
4. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R, Bombardieri E (2010) (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging 54: 100-113.
5. Department of Health MCSNi (2010) The National Cancer Survivorship Initiative Vision: Department of Health publications. www.dh.gov.uk/ publications.
6. Druce MR, Lewington V, Grossman AB (2010) Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Neuroendocrinology 91: 1-15.
7. Elliott J, Fallows A, Staetsky L, Smith PW, Foster CL, Maher EJ, Corner J (2011) The health and well-being of cancer survivors in the UK: findings from a population-based survey. Br J Cancer 105(Suppl 1): S11-S20.
8. Gedik GK, Hoefnagel CA, Bais E, Olmos RA (2008) 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35: 725-733.
9. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35: 1039-1047.
10. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27: 4162-4168.
11. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C (2012) Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol) 24: 294-308.
12. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19: 1727-1733.
13. Hatton MQ, Reed NS (1997) Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience. Clin Oncol (R Coll Radiol) 9: 385-389.
14. HMRN (2012) http://www.hmrn.org/Statistics/Incidence.aspx
15. Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, Muller-Brand J, Walter MA (2007) Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13: 6696-6702.
16. Jarufe N, McMaster P, Mayer AD, Mirza DF, Buckels JA, Orug T, Tekin K, Bramhall SR (2005) Surgical treatment of metastases to the pancreas. Surgeon 3: 79-83.
17. Jiang L, Schipper ML, Li P, Cheng Z (2009) 123I-labeled metaiodobenzylguanidine for diagnosis of neuroendocrine tumors. Rep Med Imaging 2: 79-89.
18. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB (2001a) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86: 895-902.
19. Kaltsas G, Mukherjee JJ, Plowman PN, Grossman AB (2001b) The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol (Oxf) 55: 575-587.
20. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25: 458-511.
21. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D (2011) Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38: 1788-1797.
22. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754-2762.
23. Lewington VJ (2003) Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 10: 497-501.
24. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20: 648-658.
25. Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK (2006) Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 40: 572-582.
26. Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232.
27. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-metaiodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47-60.
28. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM (2008) Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 98: 1053-1058.
29. Pape UF, Berndt U, Muller-Nordhorn J, BohmigM, Roll S, Koch M,Willich SN, Wiedenmann B (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15: 1083-1097.
30. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61: 6-32.
31. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.
32. Rinke A,Muller HH, Schade-Brittinger C, Klose KJ, Barth P,Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656-4663.
33. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight Jr GS, Tyler DS, Olson Jr. JA (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962discussion 962-3.
34. Sclafani LM, Woodruff JM, Brennan MF (1990) Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment. Surgery 108: 1124-1129discussion 1129-30.
35. Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A (2010) Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol 33: 79-82.
36. Spetz J, Dalmo J, Nilsson O, Wangberg B, Ahlman H, Forssell-Aronsson E (2012) Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma-tools for choice of radionuclide therapy. Horm Metab Res 44: 400-404.
37. Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH (2013) Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 20: 187-196.
38. Teszler CB (2013) Differentiated thyroid carcinoma after iodine-131 metaiodobenzylguanidine treatment for neuroblastoma: assessment of causality. Thyroid 23: 248-249.
39. Troncone L, Rufini V, Daidone MS, De Santis M, Luzi S (1991) [131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J Nucl Biol Med 35: 295-299.
40. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181.
41. Tsikitis VL, Wertheim BC, Guerrero MA (2012) Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer 3: 292-302.
42. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147-156.
43. van Santen HM, Tytgat GA, van de Wetering MD, van Eck-Smit BL, Hopman SM, van der Steeg AF, Nieveen van Dijkum EJ, van Trotsenburg AS (2012) Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases. Thyroid 22: 643-646.
44. Vassilopoulou-Sellin R (1998) Clinical outcome of 50 patients with malignant abdominal paragangliomas and malignant pheochromocytomas. Endocr Relat Cancer 5: 59-68.
45. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
46. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.